Clinical Trial: Efficacy and Safety of Low-Dose Upadacitinib Combined With Ustekinumab in the Treatment of Refractory Crohn's Disease

U.S., July 14 -- ClinicalTrials.gov registry received information related to the study (NCT07697547) titled 'Efficacy and Safety of Low-Dose Upadacitinib Combined With Ustekinumab in the Treatment of Refractory Crohn's Disease' on July 06.

Brief Summary: A multicenter retrospective study evaluating the effectiveness and safety of ustekinumab combined with low-dose upadacitinib in patients with refractory Crohn's disease.

Study Start Date: July 01, 2023

Study Type: OBSERVATIONAL

Condition: Inflammatory Bowel Disease (IBD) Crohn's Disease

Intervention: DRUG: Upadacitinib

Upadacitinib was administered orally at a low dose of 15 mg/day or 30 mg/day for at least 12 weeks in combination with ustekinumab.

DRUG: Ustekinumab (UST)

Ustekinu...